All In Biotech

Drug Trial Radar · NCT06016855

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

May 31, 2024

Primary completion

May 28, 2027

Study completion May 28, 2028

Sponsor

Lead sponsor
Vanderbilt-Ingram Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase IV trial evaluates how well giving standard of care (SOC) peptide receptor radionuclide therapy (PRRT) after SOC surgical removal of as much tumor as possible (debulking surgery) works in treating patients with grade 1 or 2, somatostatin receptor (SSTR) positive, gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have spread from where they first started (primary site) to the liver (hepatic metastasis). Lutetium Lu 177 dotatate is a radioactive drug that uses targeted radiation to kill tumor cells. Lutetium Lu 177 dotatate includes a radioactive form (an isotope) of the element called lutetium. This radioactive isotope (Lu-177) is attached to a molecule called dotatate. On the surface of GEP-NET tumor cells, a receptor called a somatostatin receptor binds to dotatate. When this binding occurs, the lutetium Lu 177 dotatate drug then enters somatostatin receptor-positive tumor cells, and radiation emitted by Lu-177 helps kill the cells. Giving lutetium Lu 177 dotatate after surgical debulking may better treat patients with grade 1/2 GEP-NETs

Conditions

  • Digestive System Neuroendocrine Tumor G1
  • Digestive System Neuroendocrine Tumor G2
  • Metastatic Digestive System Neuroendocrine Neoplasm
  • Metastatic Malignant Neoplasm in the Liver
  • Pancreatic Neuroendocrine Tumor G1
  • Pancreatic Neuroendocrine Tumor G2

Interventions

  • Tumor DebulkingProcedure

    Undergo surgical debulking

  • Lutetium Lu 177 DotatateDrug

    Given by IV

  • Computed TomographyProcedure

    Undergo Computed Tomography

  • Magnetic Resonance ImagingProcedure

    Undergo Magnetic Resonance Imaging

  • Copper Cu 64 DotatateDrug

    Given by IV

  • Positron Emission TomographyProcedure

    Undergo Positron Emission Tomography

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Somatostatin receptor standardized uptake values (SSTR SUV)Time frame: Up to 2 years
  2. Progression-free survivalTime frame: From the start of PRRT to the date the patient progresses radiographically or succumbs to the disease, assessed up to 2 years
  3. Overall response rateTime frame: Up to 2 years
  4. Overall survivalTime frame: From the start of PRRT to the date the patient progresses radiographically or succumbs to the disease, assessed up to 2 years
  5. Incidence of adverse eventsTime frame: Up to 2 years
  6. Gene mutationsTime frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.